Huadong Medicine Co., Ltd.
Semi-Annual Report 2023
August 16, 2023
Section I. Important Declaration, Contents and Definitions
The Board of Directors, Board of Supervisors, directors, supervisors and
senior managers of Huadong Medicine Co., Ltd. (hereinafter referred to as the
“Company”) hereby guarantee that the information presented in this semi-
annual report is authentic, accurate and complete and free of any false records,
misleading statements or material omissions, and shall undertake individual
and joint legal liabilities.
Lv Liang, the Company’s legal representative and the officer in charge of
accounting, and Qiu Renbo, head of the Accounting Department (accounting
supervisor) hereby declare and guarantee that the financial statements in this
semi-annual report are authentic, accurate and complete.
All directors have attended the board meeting to review this semi-annual
report.
The future plans, development strategies and other forward-looking
statements in this semi-annual report shall not be considered as substantial
commitment of the Company to investors. Investors and related parties should
be fully aware of the risks, and understand the differences between plans,
forecasts and commitments.
The risks the Company faces in operation include industry policy and
product price reduction risk, new drug R&D risk, investment and M&A risk,
and exchange rate fluctuation risk. For details, please refer to “X. Potential
risks and responses” in “Section III. Management Discussion and Analysis”.
Therefore, investors are kindly reminded to pay attention to possible
investment risks.
The Company does not plan to distribute cash dividends, no bonus share
will be issued, and no capital reserve will be converted to increase the share
capital.
According to “Stock Listing Rules of the Shenzhen Stock Exchange”, if
listed companies have both Chinese or other language version of public notice,
they should ensure the content of both versions are the same. In the case of
discrepancy, the original version in Chinese shall prevail.
Contents
Section I. Important Declaration, Contents and Definitions ......2
Section II. Company Profile and Key Financial Indicators......9
Section III Discussion andAnalysis of the Management ......13
Section IV. Corporate Governance ......60
Section V Environmental and Social Responsibilities ......63
Section VI. Important Matters......78
Section VII. Share Change and Shareholders......98
Section VIII. Information on Preferred Shares ...... 104
Section IX. Information on Bonds ...... 105
Section X. Financial Report...... 106
Contents of Reference File
I. Financial statements signed and stamped by the legal representative, the person
in charge of accounting work, and the head of accounting institution (accounting
manager).
II. The original of all Company’s documents publicly disclosed in the press
designated by CSRC during the reporting period and the original of announcements.
Definitions
Term refers to Definition
CSRC refers to China Securities Regulatory Commission
SSE refers to Shenzhen Stock Exchange
Huadong Medicine/the Company/our refers to Huadong Medicine Co., Ltd.
Company
CGE refers to China Grand Enterprises, Inc.
Huadong Medicine Group refers to Hangzhou Huadong Medicine Group
Co., Ltd.
Zhongmei Huadong refers to Hangzhou Zhongmei Huadong
Pharmaceutical Co., Ltd.
Jiangdong Company refers to Hangzhou Zhongmei Huadong
Pharmaceutical Jiangdong Co., Ltd.
Jiangsu Joyang Laboratories refers to Jiangsu Joyang Laboratories
Xi’an Bohua refers to Huadong Medicine (Xi’an) Bohua
Pharmaceutical Co., Ltd.
Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering
Co., Ltd.
Doer Biologics refers to Zhejiang Doer Biologics Co., Ltd.
Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd.
Chongqing Peg-Bio refers to Chongqing Peg-Bio Biop
查看PDF原文
